CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $41.58, but opened at $43.41. CRISPR Therapeutics shares last traded at $43.44, with a volume of 658,375 shares.
Analyst Upgrades and Downgrades
Several brokerages recently commented on CRSP. JMP Securities reissued a "market outperform" rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, May 21st. Chardan Capital reduced their target price on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Wall Street Zen raised shares of CRISPR Therapeutics to a "sell" rating in a research note on Friday, May 16th. Barclays decreased their price target on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a research note on Friday, May 9th. Finally, Citigroup reduced their price target on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a report on Tuesday, February 18th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, CRISPR Therapeutics has an average rating of "Hold" and a consensus price target of $71.75.
Read Our Latest Report on CRISPR Therapeutics
CRISPR Therapeutics Trading Up 5.0%
The stock's 50-day moving average is $37.96 and its 200-day moving average is $40.75. The stock has a market cap of $3.77 billion, a price-to-earnings ratio of -10.01 and a beta of 1.75.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter in the prior year, the business posted ($1.43) earnings per share. CRISPR Therapeutics's revenue was up 71.6% compared to the same quarter last year. On average, equities analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.
Insider Activity at CRISPR Therapeutics
In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the company's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider now owns 6,068 shares in the company, valued at approximately $218,083.92. This represents a 39.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is owned by insiders.
Institutional Trading of CRISPR Therapeutics
Hedge funds have recently made changes to their positions in the company. SVB Wealth LLC bought a new stake in CRISPR Therapeutics in the first quarter worth about $25,000. Costello Asset Management INC bought a new position in shares of CRISPR Therapeutics during the first quarter worth about $27,000. Wood Tarver Financial Group LLC purchased a new position in CRISPR Therapeutics in the fourth quarter valued at about $30,000. Ameriflex Group Inc. acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at $36,000. Finally, Quantbot Technologies LP boosted its holdings in CRISPR Therapeutics by 272.4% during the first quarter. Quantbot Technologies LP now owns 1,337 shares of the company's stock worth $45,000 after buying an additional 978 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
